News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Analyst action
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
An amended Schedule 13G/A filing for enGene Holdings Inc. (ENGN) indicates that a group of Venrock-affiliated investment entities and two individuals now report a 0.0% beneficial ownership of the company's Common Shares as of June 30, 2026. This means the group, previously significant holders, …
This article provides an earnings forecast for enGene Holdings Inc (ENGN), highlighting analyst ratings and future EPS and revenue growth estimates. Based on 12 analysts, the stock has a "Buy" rating with a target price indicating a 325.00% upside. The article also notes the …
enGene Therapeutics Inc. (ENGN) is a clinical-stage biotechnology company focused on developing genetic medicines for bladder cancer, with its lead product candidate, detalimogene voraplasmid, in development for non-muscle invasive bladder cancer. The company's stock is currently trading at $1.8150, showing a +0.83% change today, …
Guggenheim downgraded Engene Holdings Inc. (NASDAQ:ENGN) to Neutral from Buy following disappointing interim Phase 2 trial data for its drug detalimogene in bladder cancer, causing a 76% stock plunge. The analyst cited a decline in efficacy compared to prior analyses, placing the drug below …
This article provides an overview of enGene Holdings Inc (ENGN)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and currently has no dividend data available. The page also presents current stock pricing …
enGene Holdings Inc (ENGN) is a clinical-stage biotechnology company focusing on genetic medicines, particularly for non-muscle invasive bladder cancer. The company's stock is currently trading at $1.785, down 0.28% and has experienced an 80.23% year-to-date decline. Despite this, analysts have a "Buy" rating for …
This article provides a brief overview of enGene Holdings Inc (ENGN), showcasing its current stock price, market capitalization, and after-hours trading information. It highlights the company's stock performance with a recent drop of 3.57% and presents navigation options for financial data, discussions, and analysis …
This article provides a detailed cash flow statement for enGene Holdings Inc (ENGN), covering quarterly and annual data from FY2022Q3 to FY2026Q2, along with year-over-year percentage changes. It breaks down operating, investing, and financing cash flows, offering insights into the company's financial health. Additionally, …
This article provides a detailed risk assessment for enGene Holdings Inc (ENGN), focusing on volatility, financial, and investment risks. It presents various financial metrics including Beta, Maximum Drawdown, Volatility, Sharpe Ratio, Skewness, and Liquidity, offering 60-day, 120-day, 240-day, 3-year, and 5-year perspectives where available. …
This article provides the quarterly and annual income statements for enGene Holdings Inc (ENGN), allowing users to analyze its financial performance and operational efficiency. It presents detailed data on operating expenses, R&D expenses, depreciation, operating profit, and net income, alongside FAQs explaining how to …
This article provides a detailed balance sheet analysis for enGene Holdings Inc (ENGN), covering quarterly and annual data for various assets, liabilities, and shareholders' equity items from FY2023Q2 to FY2026Q2. It includes key financial metrics like cash and short-term investments, total assets, total liabilities, …
enGene Holdings announced that its longtime chairman, Dr. Richard Glickman, resigned on July 15, 2026, after more than 14 years of leadership. The company subsequently appointed existing director Michael Heffernan as the new chairman on July 16, 2026. This leadership change is intended to …
enGene Therapeutics Inc. has appointed Michael Heffernan as its new Chairman of the Board, replacing Dr. Richard Glickman. This leadership change occurs as the company prepares for a pre-BLA meeting with the FDA and plans to submit its BLA for detalimogene voraplasmid in the …
Search by ticker symbol or company name and select a result to open its chart.